Home Biosimilar Antibodies Immunology & Inflammation Others Pamrevlumab (anti-CTGF)
For research use only. Not for use in humans.

Pamrevlumab (anti-CTGF)

Synonyms: CCN2， HCS24

Pamrevlumab, a recombinant human antibody that binds to connective tissue growth factor (CTGF) has emerged as a potential therapy for idiopathic pulmonary fibrosis (IPF).

Pamrevlumab (anti-CTGF)

Click to purchase the isotype control of Pamrevlumab (anti-CTGF)

4 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 6.84 mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Pamrevlumab, a recombinant human antibody that binds to connective tissue growth factor (CTGF) has emerged as a potential therapy for idiopathic pulmonary fibrosis (IPF).
References

Product Details

CAS No. 946415-13-0
Isotype Human IgG1, κ
Application Pamrevlumab (anti-CTGF)
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04229004 COMPLETED Drug: Gemcitabine combined with nab-paclitaxel|Drug: Dose -m Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma Pancreatic Cancer Action Network 2020-01-31 PHASE3
NCT03941093 COMPLETED Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlu Pancreatic Cancer Non-resectable Kyntra Bio 2019-05-10 PHASE3
NCT04419558 TERMINATED Drug: Pamrevlumab|Drug: Placebo Idiopathic Pulmonary Fibrosis Kyntra Bio 2020-09-30 PHASE3
NCT04632940 TERMINATED Drug: Pamrevlumab|Drug: Placebo|Drug: Corticosteroids Duchenne Muscular Dystrophy Kyntra Bio 2021-03-03 PHASE3
NCT03955146 TERMINATED Drug: Pamrevlumab|Drug: Placebo Idiopathic Pulmonary Fibrosis Kyntra Bio 2019-06-18 PHASE3
NCT04371666 TERMINATED Drug: Pamrevlumab|Drug: Placebo|Drug: Corticosteroids Duchenne Muscular Dystrophy Kyntra Bio 2020-08-10 PHASE3

(data from https://clinicaltrials.gov, updated on 2025-04-06)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.